Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

With BIOCON's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 0.00000
forwardPE 34.08007
debtToEquity 66.25900
earningsGrowth -0.95300
revenueGrowth 0.14800
grossMargins 0.60433
operatingMargins 0.07456
trailingEps 3.20000
forwardEps 9.92000

With both earnings and revenue growth in low territory, BIOCON is likely to see shrinking profits. This signals a possible downturn in the company's financial health and may raise concerns about its future profitability.
Biocon Limited's negative gross and operating margins highlight potential financial struggles, as the company is not covering its production or operational expenses. This could lead to broader concerns about its ability to achieve profitability.
BIOCON's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that BIOCON is projected to improve its financial performance compared to the previous year.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


The recent buy bias from analysts suggests Biocon Limited is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, Biocon Limited appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.